Product Theaters

Product Theaters, located in the rear of the Exhibit Hall, offer informative sessions focusing on products or a single facet of diabetes. Product Theater sessions do not provide continuing education credit. These sessions are intended for health care professionals only with practices relevant to the presented information.

Light refreshments provided by the American Diabetes Association will be served to the first 300 attendees.

SATURDAY, JUNE 10

10:15 a.m.- 11:00 a.m.

It's Time to Rethink Professional Continuous Glucose Monitoring—The New FreeStyle Libre Pro System
*Presented by Abbott Diabetes Care*

Welcome to a new era of simplicity and convenience in professional continuous glucose monitoring. Introducing the new FreeStyle Libre Pro System—an innovative glucose assessment tool that provides a complete glycemic profile to help health care professionals make more informed treatment decisions.

**Presenter:** Daniel Einhorn, MD, FACP, FACE  
Medical Director of the Scripps Whittier Diabetes Institute  
Clinical Professor of Medicine, University of California, San Diego  
President, Diabetes and Endocrine Associates  
Associate Editor of the *Journal of Diabetes*  
La Jolla, CA

**Location:** Product Theater 1 (Booth 2537)

10:15 a.m.-11:00 a.m.

Influenza Immunization—Helping to Protect Older Adults
*Presented by Sanofi Pasteur*

Older adults are particularly vulnerable to influenza illness and the potentially life-threatening complications of influenza. Influenza often worsens comorbid health conditions, including diabetes, and older age is associated with an increased number of these conditions, as well as a progressive decline in the immune response to influenza and a diminished immune response to many vaccines, further heightening the risk. Influenza vaccination is strongly associated with a lower risk of mortality for older adults, regardless of their health status. This presentation will share information on the severe impacts of influenza in older adults, the need to optimize its prevention in this vulnerable population, and the importance of using an influenza vaccine that helps generate a greater immune response.

**Presenter:** Richard Feldman, MD  
Director of the Family Medicine Residency  
Franciscan St. Francis Health  
Indianapolis, IN

**Location:** Product Theater 2 (Booth 139)
12:15 p.m.-1:15 p.m.

Jardiance® (Empagliflozin) Tablets—A Review of Clinical Trial Data
*Presented by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly USA, LLC*

**Presenters:**
- John E. Anderson, MD
  Practicing Clinician
  The Frist Clinic
  Nashville, TN
- James R. Gavin III, MD, PhD
  CEO & Chief Medical Officer
  Healing Our Village, Inc.
  Clinical Professor of Medicine
  Emory University School of Medicine
  Atlanta, GA

**Location:**
Product Theater 1 (Booth 2537)

---

12:15 p.m.-1:15 p.m.

SGLT2 Inhibition—A Glucuretic Treatment Option for Your Adult Patients with Type 2 Diabetes
*Presented by AstraZeneca*

The kidney has an important role in the body's regulation of glucose. In patients with type 2 diabetes (T2D), the adaptive mechanism to reabsorb glucose in the kidney is thought to become maladaptive. This program will focus on the role of sodium-glucose cotransporter-2 (SGLT2) inhibition for T2D management. The clinical efficacy and safety of a SGLT2 inhibitor, including its potential place in T2D therapy, will be reviewed.

**Presenter:**
- Serge A. Jabbour, MD, FACP, FACE
  Professor of Medicine
  Director, Division of Endocrinology,
  Diabetes & Metabolic Diseases
  Sidney Kimmel Medical College at
  Thomas Jefferson University
  Philadelphia, PA

**Location:**
Product Theater 2 (Booth 139)
2:45 p.m.-3:30 p.m.
Considerations for Insulin Therapy in Adult Patients with T2DM
**Presented by Sanofi**

**Presenter:** Carol H. Wysham, MD  
Clinical Professor of Medicine  
University of Washington  
Clinical Endocrinologist  
Rockwood Center for Diabetes and Endocrinology  
Spokane, WA

**Location:** Product Theater 1 (Booth 2537)

2:45 p.m.-3:30 p.m.
Diabetes and Cardiovascular Disease: Making the Connection  
**Presented by Novo Nordisk Inc.**

This unbranded disease awareness education program explores the relationship between diabetes and cardiovascular disease (CVD). During the program, we will review established guidelines for modifying CVD risk in patients with diabetes and evaluate cardiovascular data from landmark glycemic-lowering trials.

**Presenter:** Yehuda Handelsman, MD, FACP, FNLA, MACE  
Medical Director and Principal Investigator  
Metabolic Institute of America  
Tarzana, CA

**Location:** Product Theater 2 (Booth 139)

**SUNDAY, JUNE 11**

10:15 a.m.-11:00 a.m.
Praluent® (Alirocumab) Injection—A Tailored Approach to Help Address an Unmet Need  
**Presented by Sanofi-Regeneron**

**Presenter:** Eliot A. Brinton, MD, FAHA, FNLA  
President, The Atherometabolism Institute  
Salt Lake City, UT

**Location:** Product Theater 1 (Booth 2537)
10:15 a.m.-11:00 a.m.

**Repatha® (Evolocumab) — A Focused Clinical Review**

*Presented by Amgen*

Reduction in circulating levels of low-density lipoprotein cholesterol (LDL-C) remains fundamental to major cholesterol treatment guidelines and recommendations from medical organizations. This program will review a current therapy for LDL-C lowering.

**Presenter:** Yehuda Handelsman, MD, FACP, FNLA, MACE
  - Medical Director and Principal Investigator
  - Metabolic Institute of America
  - Tarzana, CA

**Location:** Product Theater 2 (Booth 139)

12:30 p.m.-1:30 p.m.

**Awaken a Transformation in Type 2 Diabetes Management**

*Presented by Janssen Pharmaceuticals, Inc.*

This program will provide an overview of the sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of patients with type 2 diabetes. Topics include the pathophysiology of type 2 diabetes and associated cardiometabolic risk factors, how SGLT2 inhibitors work, results from active-controlled and real-world evidence studies supporting the use of SGLT2 inhibitors vs. other agents, and important safety information, followed by a question-and-answer session. This promotional education activity is not certified for continuing medical education.

**Presenters:** Carol H. Wysham, MD
  - Clinical Professor of Medicine
  - University of Washington
  - Clinical Endocrinologist
  - Rockwood Center for Diabetes and Endocrinology
  - Spokane, WA

John E. Anderson, MD
  - Practicing Clinician
  - The Frist Clinic
  - Nashville, TN

Christian Mende, MD, FACP, FACN, FASN, FASH
  - Clinical Professor of Medicine
  - University of California, San Diego
  - La Jolla, CA

**Location:** Product Theater 1 (Booth 2537)
12:30 p.m.-1:30 p.m.
The Role of a Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Therapy in Improving Glucose Control
Presented by AstraZeneca

This presentation will review the important role of glucagon-like peptide-1 (GLP-1) in physiologic glucose regulation and the mechanism of GLP-1 receptor agonists in addressing the core defects of type 2 diabetes (T2D). The clinical efficacy and safety of a once-weekly GLP-1 receptor, including results from a 3-year randomized study of patients who received a once-weekly GLP-1 receptor agonist or insulin glargine, will be discussed. In addition, the potential place in T2D therapy for this agent and a patient-centered approach to discussing treatment will be presented.

Presenter: Leigh Perreault, MD
Associate Professor of Medicine
Division of Endocrinology, Metabolism and Diabetes
Affiliate, Center for Global Health
University of Colorado Anschutz Medical Campus
Aurora, CO

Location: Product Theater 2 (Booth 139)

3:00 p.m.-3:45 p.m.
Diabetes—Treatment and Management
Presented by Sanofi

Presenter: Bruce W. Bode, MD, FACE
Practicing Clinician
Atlanta Diabetes Associates
Atlanta, GA

Location: Product Theater 1 (Booth 2537)

3:00 p.m.-3:45 p.m.
Clinical Data Review—Comparing the Safety and Efficacy of Two Once-Daily Basal Insulins in Patients with Type 1 and Type 2 Diabetes
Presented by Novo Nordisk Inc.

Objectives/Description:
• Review the study designs of two comparative clinical trials that evaluated two basal insulins.
• Discuss safety and efficacy results from these trials.

Presenter: Carol H. Wysham, MD
Clinical Professor of Medicine
University of Washington
Clinical Endocrinologist
Rockwood Center for Diabetes and Endocrinology
Spokane, WA

Location: Product Theater 2 (Booth 139)
MONDAY, JUNE 12
10:15 a.m.-11:00 a.m.

**MiniMed® 670G System with SmartGuard® HCL Technology: Driving Patient Outcomes through Automation**

*Presented by Medtronic*

Come learn about the MiniMed® 670G system—the world's first FDA-approved hybrid closed-loop system for the management of type 1 diabetes. The presenters will share clinical evidence from the pivotal trial as well as real-world experience and patient case studies.

**Presenters:** Richard M. Bergenstal, MD
Executive Director
International Diabetes Center at Park Nicollet
Minneapolis, MN

Jennifer L. Sherr, MD, PhD
Pediatric Endocrinologist and Associate Professor
Yale School of Medicine
New Haven, CT

**Location:** Product Theater 1 (Booth 2537)

10:15 a.m.-11:00 a.m.

**New Perspectives on Existing Concepts of Cardiovascular Risk**

*Presented by Amgen*

This presentation will provide a new perspective to existing cardiovascular risk factors, including modifiable and non-modifiable factors, as well as current statistics.

**Presenter:** Harold E. Bays, MD, FTOS, FACC, FACE, FNLA
Medical Director/President
Louisville Metabolic and Atherosclerosis Research Center
Louisville, KY

**Location:** Product Theater 2 (Booth 139)

12:30 p.m.-1:30 p.m.

**What's Next for the Omnipod® System? Innovation at Work**

*Presented by Insulet, Inc.*

Get a sneak peek into the next generation Omnipod Dash™ Insulin Management System and plans for the future hybrid closed-loop system.

**Presenter:** Trang Ly, MBBS, FRACP, PhD
Vice President and Medical Director
Insulet Corporation
Billerica, MA

**Location:** Product Theater 1 (Booth 2537)
Impact of the Incretin System on the Treatment of Type 2 Diabetes

Presented by Merck

Lecture Objectives:

- Understand the incretin system in T2DM.
- Discuss a treatment option for adults with T2DM.

**Presenter:** Zachary T. Bloomgarden, MD, MACE
Clinical Professor of Medicine
Mt. Sinai School of Medicine
New York, NY

**Location:** Product Theater 2 (Booth 139)